---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: References"
description: "Reference list for the formulary evidence report on Ersodetug (RZ358) in Tumor hyperinsulinism. 140 cited documents."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: References

<a id="references"></a>

## 5 References

1. [Afinitor prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022334s055lbl.pdf)
2. [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)
3. [Bernard et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23392213/)
4. [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)
5. [Boss et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11619583/)
6. [Brown et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29205458/)
7. [Cabometyx prescribing information (2025)](http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208692s019lbl.pdf)
8. [Cahn et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37195951/)
9. [Chida et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11465228/)
10. [Christ et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24622317/)
11. [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)
12. [ClinicalTrials.gov NCT04538989 results](https://clinicaltrials.gov/study/NCT04538989?tab=results)
13. [ClinicalTrials.gov NCT05735912](https://clinicaltrials.gov/study/NCT05735912)
14. [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)
15. [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)
16. [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970)
17. [Corbin et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3929448/)
18. [Crinò et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36871765/)
19. [Crippa et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22430908/)
20. [Cryer et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19088155/)
21. [Dai et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31292840/)
22. [Dastamani et al. (2024)](https://abstracts.eurospe.org/hrp/0098/hrp0098fc14.3)
23. [de Carbonnières et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33975801/)
24. [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)
25. [Dizon et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10190379/)
26. [Dynkevich et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23671155/)
27. [eCQI Resource Center CMS816v5 (2026)](https://ecqi.healthit.gov/ecqm/hosp-inpt/2026/cms0816v5)
28. [El Sayed et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8606734/)
29. [EMA congenital hyperinsulinism orphan designation (2016)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1702)
30. [EMA insulinoma orphan designation (2024)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2879)
31. [ENDO Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/ENDO_2026_ORF10_sunRIZE_Demirbilek_13June.pdf)
32. [EU Clinical Trials Information System 2024-515447-36-00](https://euclinicaltrials.eu/ctis-public/view/2024-515447-36-00)
33. [FDA Orphan Drug Designations and Approvals (2015)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=430714)
34. [FDA Orphan Drug Designations and Approvals (2024)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=966723)
35. [Friebe et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671384/)
36. [Fukuda et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16860583/)
37. [Gill et al. (1997)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2431498/)
38. [Guerrero-Pérez et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43000590/)
39. [Gvoke prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212097s012lbl.pdf)
40. [Habibollahi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32541627/)
41. [Hackeng et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36779771/)
42. [Halfdanarson et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32675783/)
43. [Hendren et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29055143/)
44. [Hirshberg et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10999812/)
45. [Hirshberg et al. (2005)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4136659/)
46. [Hoff and Vassilopoulou-Sellin (1998)](https://pubmed.ncbi.nlm.nih.gov/9554538/)
47. [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)
48. [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)
49. [Howarth et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788970/)
50. [Howe et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7029300/)
51. [Ito et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/24499825/)
52. [Ito et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8531106/)
53. [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)
54. [Journal of Clinical Endocrinology and Metabolism insulinoma correction (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13271780/)
55. [Jürgensen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37931914/)
56. [Karamanolis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11342107/)
57. [Koch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40439997/)
58. [Komatsu et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26598136/)
59. [Kulke et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19129539/)
60. [Kurakawa et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34343300/)
61. [Linch et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8643969/)
62. [Lundholm et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40288609/)
63. [Lutathera prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208700Orig1s032lbl.pdf)
64. [Masharani et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11954510/)
65. [NCCN Neuroendocrine and Adrenal Tumors guideline](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1448)
66. [Niitsu et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30504655/)
67. [Nockel et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8058619/)
68. [Osataphan et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10506502/)
69. [Osataphan et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37888936/)
70. [Patel et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6150619/)
71. [Patel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42362418/)
72. [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)
73. [Pattison et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40424062/)
74. [Pavel et al. (2020)](https://doi.org/10.1016/j.annonc.2020.03.304)
75. [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)
76. [Peltola et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6218736/)
77. [Peltola et al. (2021a)](https://pubmed.ncbi.nlm.nih.gov/32974918/)
78. [Peltola et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8784472/)
79. [Placzkowski et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19141587/)
80. [Proglycem prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/017453s025lbl.pdf)
81. [Rezolute congenital HI breakthrough therapy release (2025)](https://ir.rezolutebio.com/news/detail/345/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycemia-due-to-congenital-hyperinsulinism)
82. [Rezolute congenital HI FDA meeting release (2026)](https://ir.rezolutebio.com/news/detail/373/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting)
83. [Rezolute EAP patient profiles (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-2.htm)
84. [Rezolute ENDO presentations release (2026)](https://ir.rezolutebio.com/news/detail/380/rezolute-highlights-results-presented-from-natural-history-outcomes-studies-and-its-ersodetug-clinical-program-in-hyperinsulinism-at-annual-meeting-of-the-endocrine-society)
85. [Rezolute FDA review update release (2026)](https://ir.rezolutebio.com/news/detail/383/rezolute-provides-update-on-fda-review-of-its-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)
86. [Rezolute first quarter fiscal 2027 results release (2026)](https://ir.rezolutebio.com/news/detail/388/rezolute-reports-first-quarter-fiscal-2027-financial-results-and-provides-business-update)
87. [Rezolute for patients page](https://rezolutebio.com/for-patients)
88. [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)
89. [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)
90. [Rezolute investor event presentation (2025)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925109559/tm2530840d1_ex99-1.htm)
91. [Rezolute January corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-3.htm)
92. [Rezolute NICTH validation release (2024)](https://ir.rezolutebio.com/news/detail/327/rezolute-reports-validation-of-the-potential-use-of-rz358-for-treatment-of-non-islet-cell-tumor-hypoglycemia-nicth)
93. [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)
94. [Rezolute partial clinical hold release (2024)](https://ir.rezolutebio.com/news/detail/339/fda-lifts-partial-clinical-holds-on-rz358-for-the-treatment-of-congenital-hyperinsulinism-and-authorizes-u-s-inclusion-in-ongoing-phase-3-study)
95. [Rezolute pre-BLA recommendation release (2026)](https://ir.rezolutebio.com/news/detail/385/rezolute-announces-fda-recommendation-to-hold-a-pre-bla-meeting-as-a-precursor-to-submitting-a-biologics-license-application-bla-for-congenital-hyperinsulinism)
96. [Rezolute prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926126478/tm2627558-6_424b5.htm)
97. [Rezolute RIZE PES data release (2022)](https://ir.rezolutebio.com/news/detail/299/rezolute-announces-positive-data-from-its-phase-2b-rize-study-of-rz358-in-patients-with-congenital-hyperinsulinism)
98. [Rezolute RIZE topline release (2022)](https://ir.rezolutebio.com/news/detail/296/rezolute-announces-positive-results-from-the-phase-2b-rize-study-of-rz358-in-congenital-hyperinsulinism)
99. [Rezolute second quarter fiscal 2024 results release (2024)](https://ir.rezolutebio.com/news/detail/326/rezolute-reports-second-quarter-fiscal-2024-results-and-provides-business-update)
100. [Rezolute September corporate presentation (2025)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925085892/tm2524786d1_ex99-2.htm)
101. [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)
102. [Rezolute sunRIZE PES presentation release (2026)](https://ir.rezolutebio.com/news/detail/375/rezolute-announces-oral-presentation-of-results-from-its-phase-3-sunrize-study-of-ersodetug-in-patients-with-congenital-hyperinsulinism-at-the-pediatric-endocrine-society-annual-meeting)
103. [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)
104. [Rezolute third quarter fiscal 2024 results release (2024)](https://ir.rezolutebio.com/news/detail/329/rezolute-reports-third-quarter-fiscal-2024-financial-results-and-provides-business-update)
105. [Rezolute tumor HI breakthrough therapy release (2025)](https://ir.rezolutebio.com/news/detail/354/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism)
106. [Rezolute tumor HI evidence release (2023)](https://ir.rezolutebio.com/news/detail/318/rezolute-announces-further-evidence-of-rz358s-efficacy-in-tumor-mediated-hyperinsulinism)
107. [Rezolute tumor HI IND clearance release (2024)](https://ir.rezolutebio.com/news/detail/337/rezolute-announces-fda-clearance-of-ind-application-for-phase-3-registrational-study-of-rz358-for-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism)
108. [Rezolute tumor HI orphan drug designation release (2024)](https://ir.rezolutebio.com/news/detail/343/fda-grants-orphan-drug-designation-to-rezolutes-ersodetug-rz358-for-the-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism)
109. [Rezolute upLIFT design alignment release (2025)](https://ir.rezolutebio.com/news/detail/361/rezolute-announces-alignment-with-fda-on-streamlined-design-for-ongoing-phase-3-trial-of-ersodetug-in-tumor-hyperinsulinism)
110. [Rezolute upLIFT enrollment completion release (2026)](https://ir.rezolutebio.com/news/detail/386/rezolute-announces-completion-of-enrollment-in-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)
111. [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)
112. [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)
113. [Rizzatti et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12550746/)
114. [Ryan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12268652/)
115. [Sada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7678752/)
116. [Sada et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32873371/)
117. [Sandostatin LAR Depot prescribing information (2024)](http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021008s049lbl.pdf)
118. [Schubert et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37888935/)
119. [Service et al. (1991)](https://pubmed.ncbi.nlm.nih.gov/1677058/)
120. [Signifor prescribing information (2024)](http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/200677s012lbl.pdf)
121. [Somatuline Depot prescribing information (2024)](http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022074s032lbl.pdf)
122. [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf)
123. [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)
124. [Svensson et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9210785/)
125. [Teale and Marks (1998)](https://pubmed.ncbi.nlm.nih.gov/9876347/)
126. [Teale and Wark (2004)](https://pubmed.ncbi.nlm.nih.gov/15049960/)
127. [Vega-Beyhart et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40165498/)
128. [Veltroni et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32061159/)
129. [Vezzosi et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15879362/)
130. [Vezzosi et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18031316/)
131. [Vu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10959053/)
132. [WHO INN Proposed List 128 (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl128.pdf)
133. [Wiese et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10310606/)
134. [XOMA (2014)](https://investors.xoma.com/news-events/press-releases/detail/258/xoma-launches-xoma-358-clinical-development)
135. [XOMA (2015)](https://investors.xoma.com/news-events/press-releases/detail/267/xoma-presents-positive-phase-1-xoma-358-data-at-the-endo)
136. [XOMA Form 10-K (2015)](https://www.sec.gov/Archives/edgar/data/791908/000114036115011358/form10k.htm)
137. [XOMA Form 10-K (2016)](https://www.sec.gov/Archives/edgar/data/791908/000156459016014295/xoma-10k_20151231.htm)
138. [XOMA Form 10-Q (2015)](https://www.sec.gov/Archives/edgar/data/791908/000156459015009798/xoma-10q_20150930.htm)
139. [Yamada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7232294/)
140. [Zandee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30566620/)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
